# Marrow leptin-LEPR signaling rewires mitochondrial oxidative metabolism to confer chemoresistance in acute myeloid leukemia

**Authors:** Xinai Liao, Wei Dai, Xiaolin Xu, Danni Cai, Maoqing Tan, Zukai Wang, Yanrong Huang, Diyu Hou, Jingru Liu, Liuhuan Wang, Jin Wang, Xiaoting Wang, Shuxia Zhang, Xinjian Lin, Huifang Huang

PMC · DOI: 10.1038/s41419-026-08528-0 · 2026-02-23

## TL;DR

High levels of leptin in bone marrow help leukemia cells resist chemotherapy by changing their energy use, and blocking leptin receptors can restore treatment effectiveness.

## Contribution

Identifies a new metabolic mechanism of chemoresistance in AML driven by marrow leptin-LEPR signaling and shows that LEPR blockade can restore chemosensitivity.

## Key findings

- Elevated marrow leptin and LEPR levels correlate with poor Ara-C clearance and reduced AML patient survival.
- Leptin activates JAK2/STAT3 signaling, boosts mitochondrial activity, and protects blasts from drug-induced oxidative damage.
- Blocking LEPR with Allo-aca restores chemosensitivity without affecting baseline leukemia growth.

## Abstract

Leptin is abundant within marrow adipose tissue, yet its impact on acute myeloid leukemia (AML) therapy response is undefined. Here, we report that elevated bone-marrow leptin and blast-cell leptin-receptor (LEPR) levels strongly associate with poor cytarabine (Ara-C) clearance and reduced survival in newly diagnosed AML patients. Mechanistic and functional validation in human AML lines, primary blasts, and two syngeneic mouse models (MLL-AF9, AML1-ETO9a) shows that exogenous leptin markedly blunts Ara-C cytotoxicity, whereas the high-affinity LEPR antagonist Allo-aca restores chemosensitivity without altering baseline leukemia growth. Leptin up-regulates LEPR and triggers JAK2/STAT3 signaling that boosts mitochondrial complex Ⅰ activity, oxidative phosphorylation, and mitochondrial reactive oxygen species (mtROS); the resulting mtROS surge activates a compensatory antioxidant program that shields blasts from drug-induced oxidative damage. These data identify an adipokine-driven metabolic circuit governing AML chemoresistance and reveal LEPR blockade as a tractable strategy to improve outcomes, underscoring adipose–tumor crosstalk as a general therapeutic vulnerability.

## Linked entities

- **Genes:** LEPR (leptin receptor) [NCBI Gene 3953], JAK2 (Janus kinase 2) [NCBI Gene 3717], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774]
- **Chemicals:** leptin (PubChem CID 157010069), cytarabine (PubChem CID 6253), Allo-aca (PubChem CID 162678834)
- **Diseases:** acute myeloid leukemia (MONDO:0015667), AML (MONDO:0018874)

## Full-text entities

- **Genes:** Gpx1 (glutathione peroxidase 1) [NCBI Gene 14775] {aka CGPx, GPx-1, GSHPx-1, Gpx}, CEBPD (CCAAT enhancer binding protein delta) [NCBI Gene 1052] {aka C/EBP-delta, CELF, CRP3, NF-IL6-beta}, TOMM20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 9804] {aka MAS20, MOM19, TOM20}, Mllt3 (myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3) [NCBI Gene 70122] {aka 2210011H10Rik, 2610012I03Rik, 3830408D16Rik, Af9, D4Ertd321e}, LEPR (leptin receptor) [NCBI Gene 3953] {aka CD295, LEP-R, LEPRD, OB-R, OBR, huB219}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, CD34 (CD34 molecule) [NCBI Gene 947], FANCB (FA complementation group B) [NCBI Gene 2187] {aka FA2, FAAP90, FAAP95, FAB, FACB}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, GCLC (glutamate-cysteine ligase catalytic subunit) [NCBI Gene 2729] {aka CNSHA7, GCL, GCS, GLCL, GLCLC}, Lep (leptin) [NCBI Gene 16846] {aka ob, obese}, Sod2 (superoxide dismutase 2, mitochondrial) [NCBI Gene 20656] {aka MnSOD, Sod-2}, Kmt2a (lysine (K)-specific methyltransferase 2A) [NCBI Gene 214162] {aka 6430520K01, ALL-1, All1, Cxxc7, HRX, HTRX1}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, Sod1 (superoxide dismutase 1, soluble) [NCBI Gene 20655] {aka B430204E11Rik, Cu/Zn-SOD, CuZnSOD, Ipo-1, Ipo1, SODC}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, MLLT3 (MLLT3 super elongation complex subunit) [NCBI Gene 4300] {aka AF9, YEATS3}, Nqo1 (NAD(P)H dehydrogenase, quinone 1) [NCBI Gene 18104] {aka Dia4, Dtd, Nmo-1, Nmo1, Nmor1, Ox-1}, Runx1 (runt related transcription factor 1) [NCBI Gene 12394] {aka AML1, CBF-alpha-2, Cbfa2, Pebp2a2, Pebpa2b}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Gclm (glutamate-cysteine ligase, modifier subunit) [NCBI Gene 14630] {aka Gcmc, Glclr}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, GSTK1 (glutathione S-transferase kappa 1) [NCBI Gene 373156] {aka GST, GST 13-13, GST13, GST13-13, GSTK1-1, hGSTK1}, Gclc (glutamate-cysteine ligase, catalytic subunit) [NCBI Gene 14629] {aka D9Wsu168e, GLCL-H, Ggcs-hs, Glclc}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, Atf4 (activating transcription factor 4) [NCBI Gene 11911] {aka Atf-4, C/ATF, CREB-2, CREB2, TAXREB67}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Lepr (leptin receptor) [NCBI Gene 16847] {aka B219, LEP-R, LEPROT, Leprb, Modb1, OB-RGRP}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, KMT2A (lysine methyltransferase 2A) [NCBI Gene 4297] {aka ALL-1, ALL1, CXXC7, GAS7, HRX, HTRX}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}
- **Diseases:** hematologic malignancy (MESH:D019337), AML (MESH:D015470), obesity (MESH:D009765), gallbladder cancer (MESH:D005706), carcinogenesis (MESH:D063646), cachexia (MESH:D002100), cancer (MESH:D009369), multiple myeloma (MESH:D009101), hepatosplenomegaly (MESH:C535727), cytotoxic injury (MESH:D014947), breast cancer (MESH:D001943), adiposity (MESH:D018205), APL (MESH:D015473), FAO (MESH:C536560), colorectal cancer (MESH:D015179), leukemia (MESH:D007938), extramedullary disease (MESH:D023981), Blood Diseases (MESH:D006402), tumorigenic (MESH:D002471)
- **Chemicals:** CCK-8 (MESH:D012844), DNR (MESH:D003630), JSI-124 (MESH:C038106), free fatty acids (MESH:D005230), venetoclax (MESH:C579720), IACS-010759 (MESH:C000710313), oxygen (MESH:D010100), PBS (MESH:D007854), PEITC (MESH:C058305), MitoSOX (MESH:C521281), ROS (MESH:D017382), Azacitidine (MESH:D001374), Ara-C (MESH:D003561), GSH (MESH:D005978), ATP (MESH:D000255), lipids (MESH:D008055), polybrene (MESH:D006583), MitoTEMPO (MESH:C555916), fatty acid (MESH:D005227), GSSG (MESH:D019803), H&amp;E (MESH:D006371), Allo-aca (-), superoxide (MESH:D013481), puromycin (MESH:D011691)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MA9 — Homo sapiens (Human), Glycogen storage disease type V, Induced pluripotent stem cell (CVCL_C7T7), CCK-8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), Allo-aca — Mus musculus (Mouse), Conditionally immortalized cell line (CVCL_5F75), AE9a — Mus musculus (Mouse), Hybridoma (CVCL_XH84), MLL-AF9 — Mus musculus (Mouse), Embryonic stem cell (CVCL_VC44), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), U937 — Homo sapiens (Human), Adult acute monocytic leukemia, Cancer cell line (CVCL_0007), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12966444/full.md

---
Source: https://tomesphere.com/paper/PMC12966444